Table 3.

Antifungal Prophylaxis and Invasive Fungal Site of Infection

	Episodes (Total = 72), No. (%) of Unique Patients
Antifungal prophylaxis prior to IFI*
Fluconazole	7 (12.2)
Micafungin	3 (5.2)
Voriconazole	2 (3.5)
Primary site of infection while receiving CAF†
Pulmonary	31 (47.3)
Multifocal‡	26 (33.3)
CNS/brain	4 (5.2)
Skin	3 (5.2)
Sinus	2 (3.5)
Blood	2 (3.5)
Bone	1 (1.7)
Other	3 (5.2)

CAF, combination antifungal therapy; IFI, invasive fungal infection

* Antifungal prophylaxis prior to diagnosis of IFI was defined as the number of patients who received antifungal prophylaxis at the time of IFI diagnosis.

^† There were 3 unique patients who had multiple CAF episodes who had a diagnosis of either pulmonary or multifocal IFI.

^‡ Multifocal disease is defined as IFI identified in multiple sites.